Pain
📧 Sign up to get email alerts when something new happens for Pain.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2024-10-31FDA Approved: METHADONE HYDROCHLORIDE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for methadone hydrochloride from Hikma Pharmaceuticals USA Inc., supporting its continued availabili…
-
FDA approval · 2024-10-31FDA Approved: DILAUDID — Supplemental Application (Rhodes Pharmaceuticals L.P.)
FDA approved a supplemental application for DILAUDID (hydromorphone hydrochloride) filed by Rhodes Pharmaceuticals L.P.
-
FDA approval · 2024-10-31FDA Approved: ACETAMINOPHEN AND CODEINE PHOSPHATE — Supplemental Application (Strides Pharma Science Limited)
FDA approved a supplemental application for an acetaminophen and codeine phosphate product submitted by Strides Pharma Science Limited.
-
FDA approval · 2024-10-31FDA Approved: HYDROCODONE BITARTRATE AND ACETAMINOPHEN — Supplemental Application (Aurolife Pharma, LLC)
FDA approved a supplemental application for a generic hydrocodone bitartrate and acetaminophen product manufactured by Aurolife Pharma, LLC.
-
FDA approval · 2024-10-31FDA Approved: TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN — Supplemental Application (Micro Labs Limited)
FDA granted supplemental approval to Micro Labs Limited for a tramadol hydrochloride and acetaminophen combination generic product (ANDA 201…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2024-10-31FDA Approved: OXYCODONE HYDROCHLORIDE — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved a supplemental application for Lupin Pharmaceuticals' generic oxycodone hydrochloride product (ANDA 204603).
-
FDA approval · 2024-10-31FDA Approved: MS CONTIN — Supplemental Application (Rhodes Pharmaceuticals L.P.)
The FDA approved a supplemental application for MS CONTIN (morphine sulfate) from Rhodes Pharmaceuticals L.P., indicating an approved supple…
-
FDA approval · 2024-10-31FDA Approved: TRAMADOL HYDROCHLORIDE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for tramadol hydrochloride from Aurobindo Pharma Limited.
-
FDA approval · 2024-10-31FDA Approved: FENTANYL SYSTEM — Supplemental Application (ALVOGEN)
FDA approved a supplemental application for the FENTANYL SYSTEM from ALVOGEN.
-
FDA approval · 2024-10-31FDA Approved: ACETAMINOPHEN AND CODEINE PHOSPHATE — Supplemental Application (PAI Holdings, LLC dba PAI Pharma)
FDA approved a supplemental application for acetaminophen and codeine phosphate from PAI Holdings (PAI Pharma).
-
FDA approval · 2024-10-31FDA Approved: APADAZ — Supplemental Application (Zevra Therapeutics, Inc.)
The FDA approved a supplemental application for APADAZ (benzhydrocodone and acetaminophen) from Zevra Therapeutics, Inc. The action involves…
-
FDA approval · 2024-10-31FDA Approved: FENTANYL TRANSDERMAL — Supplemental Application (SpecGx LLC)
FDA approved a supplemental application for fentanyl transdermal from SpecGx LLC. The approval represents a modification to the existing pro…
-
FDA approval · 2024-10-31FDA Approved: HYDROCODONE BITARTRATE AND ACETAMINOPHEN — Supplemental Application (Elite Laboratories, Inc.)
The FDA granted supplemental approval for a hydrocodone bitartrate and acetaminophen product from Elite Laboratories, Inc. under ANDA209924,…
-
FDA approval · 2024-10-31FDA Approved: METHADONE HYDROCHLORIDE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for methadone hydrochloride from Hikma Pharmaceuticals USA Inc., confirming the generic product's ap…
-
FDA approval · 2024-10-31FDA Approved: ACETAMINOPHEN AND CODEINE PHOSPHATE — Supplemental Application (Strides Pharma Science Limited)
The FDA approved a supplemental application for Strides Pharma Science Limited for acetaminophen and codeine phosphate tablets, a generic an…
-
FDA label_change · 2024-10-31FDA Approved: XTAMPZA ER — Supplemental Application (Collegium Pharmaceutical, Inc.)
The FDA approved a supplemental application for XTAMPZA ER (oxycodone) from Collegium Pharmaceutical to update the product labeling. XTAMPZA…
-
FDA approval · 2024-10-31FDA Approved: HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE — Supplemental Application (Novel Laboratories, Inc.)
FDA approved a supplemental application for the generic Hydrocodone Bitartrate and Homatropine Methylbromide from Novel Laboratories, Inc.
-
FDA approval · 2024-10-31FDA Approved: HYDROCODONE BITARTRATE — Supplemental Application (Alvogen Inc.)
FDA approved a supplemental application for hydrocodone bitartrate from Alvogen Inc., under the ANDA process.
-
FDA approval · 2024-10-31FDA Approved: OXYCODONE HYDROCHLORIDE — Supplemental Application (MAJOR PHARMACEUTICALS)
The FDA approved a supplemental application for oxycodone hydrochloride from Major Pharmaceuticals under an ANDA.
-
CLINICAL_TRIALS research · 2024-10-31Clinical Trial Update: Distress in Adolescents With Chronic Pain: Who is at Risk, When, and Why
This clinical trial update from the University of Oxford describes research on distress in adolescents with chronic pain, aiming to identify…
-
CLINICAL_TRIALS trial_result · 2024-10-29Clinical Trial Update: Effects of Transcutaneous Vagus Nerve Stimulation (taVNS) in Individuals With Primary Dysmenorrhea [NA]
A completed clinical trial evaluated transcutaneous vagus nerve stimulation (taVNS) for primary dysmenorrhea; no results are provided in thi…
-
CLINICAL_TRIALS trial_result · 2024-10-29Clinical Trial Update: The Impact Of Fascia Thickness on Chronic Low Back Pain
A completed clinical trial evaluated the relationship between fascia thickness and chronic low back pain.
-
CLINICAL_TRIALS research · 2024-10-28Clinical Trial Update: Embo Registry; National Registry for Artery Embolization
Clinical trial registry update for the Embo Registry and National Registry for Artery Embolization. It lists recruiting status for chronic p…
-
CLINICAL_TRIALS trial_result · 2024-10-26Clinical Trial Update: Single-Session "Empowered Relief" Class for Marfan Syndrome and Related Conditions [NA]
Stanford's clinical trial update reports the completion of a single-session 'Empowered Relief' class for Marfan syndrome and related conditi…
-
CLINICAL_TRIALS withdrawal · 2024-10-26Clinical Trial Update: Apply the PD Model of Peripheral Oxytocin Action to a Multimodal Stimulus [Phase 2]
A Phase 2 clinical trial involving oxytocin's peripheral action in response to a multimodal stimulus was withdrawn.